Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Has consented to participate in this study.~* Taking opioid therapy for persistent non-cancer pain.~* Has bowel dysfunction mainly due to opioids.~* Has bowel dysfunction since starting opioids as defined by infrequent bowel movements and additional bowel-related symptoms.~* Willing to discontinue laxative therapy (will be provided study-specific standardized laxative if needed).~* Willing to report daily bowel symptoms.~Exclusion criteria:~* Pregnant, lactating, or planning to become pregnant.~* Not ambulatory.~* Participated in another trial with an investigational drug in the past 30 days.~* Taking opioids for the management of drug addiction or cancer-related pain.~* Severe constipation whereby the subject is at immediate risk of developing serious complications of constipation.~* Gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.~* HIV-infected, has active hepatitis, or has ever been infected with hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Alvimopan 0.5 mg once daily (Type: EXPERIMENTAL): None
- alvimopan 0.5 mg twice daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).